Research progress of HIV-1 drug resistance mutations / 中国人兽共患病学报

ABSTRACT

By the end of 2015,all over the world there were around 17 million HIV/AIDS cases received antiretroviral therapy,the HIV-1 morbidity and mortality decreased rapidly.With antiretroviral treatment to all HIV infected persons,HIV resistance mutation is also a threat to the long-term treatment and also,had a negative impact on the important public health strategy of the global elimination in 2030.This review attempts to proceed from different economic and geographical environment,describing genetic barrier of commonly used antiretroviral drugs,the degree of their cross-reactions,and the epidemiology and management of drug-resistant mutations from the individual and group levels.The paper also summarizes the prevalent modes of transmitted drug resistance (TDR) and acquired drug resistance (ADR) in both high-income and low-and middle-income countries (LMICs),and analyze the two kind problems of public health significance to HIV resistant mutations,i.e.pretreatment resistance (PDR) and preexposure prophylaxis (PREP).In addition,in view of effectivel HIV cases of treatment and management in different countries,this paper also analyzes the genotypic resistance testing and treatment practices related to AIDS prevention and control.The content has a certain reference function to our country.